Literature DB >> 26945342

Diagnostic criteria for cancer cachexia: data versus dogma.

Lisa Martin1.   

Abstract

PURPOSE OF REVIEW: Cachexia limits cancer therapy, quality of life, and survival of patients with cancer. Challenges identifying and diagnosing cachexia are due to disparities in diagnostic criteria. A framework for classification of cancer cachexia was recently defined by international consensus. This review describes recent efforts to use this framework to develop definitive diagnostic criteria for cancer cachexia. RECENT
FINDINGS: The principle proposed in the cancer cachexia framework for development of diagnostic criteria is that 'definitive cutoffs for variables could be determined from large contemporary datasets by determining the values that relate optimally to meaningful patient-centered outcomes.' Clearly defined statistical methods to examine distributions of diagnostic criteria in relation to an outcome are used to achieve this task. As a first step, a dataset of more than 11 000 cancer patients from Europe and Canada was compiled, and used to develop and validate a new grading system for cancer-associated weight loss, based on a risk stratification with survival as the outcome. The next refinements for diagnostic criteria will be enabled by the emergence of rich datasets including key variables further specifying the nature of cachexia such as skeletal muscle depletion, reduced food intake, and inflammation.
SUMMARY: Development of diagnostic criteria for cancer cachexia is based on a solid conceptual foundation and is moving toward defining the type of assessments, optimal values, and combinations of criteria that best define cachexia. Large contemporary datasets representing different cancer populations, candidate cachexia diagnostic criteria, and clinical outcomes will further ensure developmental and validation efforts.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26945342     DOI: 10.1097/MCO.0000000000000272

Source DB:  PubMed          Journal:  Curr Opin Clin Nutr Metab Care        ISSN: 1363-1950            Impact factor:   4.294


  12 in total

1.  Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study).

Authors:  Bette J Caan; Jeffrey A Meyerhardt; Candyce H Kroenke; Stacey Alexeeff; Jingjie Xiao; Erin Weltzien; Elizabeth Cespedes Feliciano; Adrienne L Castillo; Charles P Quesenberry; Marilyn L Kwan; Carla M Prado
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-05-15       Impact factor: 4.254

Review 2.  Progress in Research on Antitumor Drugs and Dynamic Changes in Skeletal Muscles.

Authors:  Ting Xu; Zhen-Hao Li; Ting Liu; Cai-Hong Jiang; Ya-Juan Zhang; Hui Li; Ying Jiang; Juan Zhao; Wen-Jing Guo; Jia-Yuan Guo; Lu Wang; Jia-Xuan Li; Jing Shen; Gao-Wa Jin; Ze-Wei Zhang; Quan-Fu Li
Journal:  Front Pharmacol       Date:  2022-07-06       Impact factor: 5.988

3.  Tumor cell anabolism and host tissue catabolism-energetic inefficiency during cancer cachexia.

Authors:  Mangala Hegde; Uzini Devi Daimary; Sosmitha Girisa; Aviral Kumar; Ajaikumar B Kunnumakkara
Journal:  Exp Biol Med (Maywood)       Date:  2022-05-06

4.  ZIP4 Promotes Muscle Wasting and Cachexia in Mice With Orthotopic Pancreatic Tumors by Stimulating RAB27B-Regulated Release of Extracellular Vesicles From Cancer Cells.

Authors:  Jingxuan Yang; Zicheng Zhang; Yuqing Zhang; Xiaoling Ni; Guohua Zhang; Xiaobo Cui; Mingyang Liu; Can Xu; Qiang Zhang; Huiyun Zhu; Jie Yan; Vivian F Zhu; Yusheng Luo; John P Hagan; Zhaoshen Li; Jing Fang; Aminah Jatoi; Martin E Fernandez-Zapico; Lei Zheng; Barish H Edil; Michael S Bronze; Courtney W Houchen; Yi-Ping Li; Min Li
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 22.682

5.  Low skeletal muscle radiation attenuation and visceral adiposity are associated with overall survival and surgical site infections in patients with pancreatic cancer.

Authors:  David P J van Dijk; Maikel J A M Bakens; Mariëlle M E Coolsen; Sander S Rensen; Ronald M van Dam; Martijn J L Bours; Matty P Weijenberg; Cornelis H C Dejong; Steven W M Olde Damink
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-10-26       Impact factor: 12.910

6.  A pilot study of radiologic measures of abdominal adiposity: weighty contributors to early pancreatic carcinogenesis worth evaluating?

Authors:  Jennifer B Permuth; Jung W Choi; Dung-Tsa Chen; Kun Jiang; Gina DeNicola; Jian-Nong Li; Domenico Coppola; Barbara A Centeno; Anthony Magliocco; Yoganand Balagurunathan; Nipun Merchant; Jose G Trevino; Daniel Jeong
Journal:  Cancer Biol Med       Date:  2017-02       Impact factor: 4.248

7.  A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women.

Authors:  Traver J Wright; E Lichar Dillon; William J Durham; Albert Chamberlain; Kathleen M Randolph; Christopher Danesi; Astrid M Horstman; Charles R Gilkison; Maurice Willis; Gwyn Richardson; Sandra S Hatch; Daniel C Jupiter; Susan McCammon; Randall J Urban; Melinda Sheffield-Moore
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-04-14       Impact factor: 12.910

8.  Racial and ethnic disparities in a state-wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities.

Authors:  Jennifer B Permuth; Ashley Clark Daly; Daniel Jeong; Jung W Choi; Miles E Cameron; Dung-Tsa Chen; Jamie K Teer; Tracey E Barnett; Jiannong Li; Benjamin D Powers; Nagalakshmi B Kumar; Thomas J George; Karla N Ali; Tri Huynh; Shraddha Vyas; Clement K Gwede; Vani N Simmons; Pamela J Hodul; Estrella M Carballido; Andrew R Judge; Jason B Fleming; Nipun Merchant; Jose G Trevino
Journal:  Cancer Med       Date:  2019-05-09       Impact factor: 4.452

9.  Does perioperative oxandrolone improve nutritional status in patients with cachexia related to head and neck carcinoma?

Authors:  Angela M Osmolak; Cristine N Klatt-Cromwell; Amber M Price; Jose A Sanclement; Greg A Krempl
Journal:  Laryngoscope Investig Otolaryngol       Date:  2019-05-15

10.  Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer.

Authors:  Jie Lee; Jhen-Bin Lin; Meng-Hao Wu; Ya-Ting Jan; Chih-Long Chang; Chueh-Yi Huang; Fang-Ju Sun; Yu-Jen Chen
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-05-15       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.